HOS4 Antibody

What is HOS4 Antibody and what does it target?

Based on available research, "HOS4 Antibody" may refer to several distinct targets:

• Antibodies targeting HOXC4 (Homeobox C4), a transcription factor belonging to the HOX gene family that plays crucial roles in developmental processes

• Antibodies against HOXB4 (Homeobox protein Hox-B4), involved in hematopoietic stem cell regulation

• Antibodies recognizing histone H4, particularly its acetylated forms

• Potentially antibodies against the yeast HOS4 protein, a component of the Set3C complex involved in chromatin remodeling

The most well-characterized of these is the HOXC4 Polyclonal Antibody, which targets a protein that functions as a sequence-specific transcription factor and is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis .

What are the primary applications of HOS4 Antibody in research?

HOXC4 antibodies are utilized in several experimental techniques:

These applications allow researchers to:

• Study developmental processes including embryogenesis

• Investigate hematopoiesis and lymphoid cell differentiation

• Examine HOXC4 expression in keratinocytes and other tissue types

For histone H4 antibodies, applications focus on studying chromatin structure and modifications, particularly acetylation patterns that play roles in gene expression regulation .

How does the specificity of antibodies to histone H4 modifications impact experimental design?

Antibody specificity for histone modifications is critical when studying epigenetic regulation. Research has demonstrated:

• Antibodies can be generated with specificity for particular acetylation patterns on histone H4

• Studies have used antibodies specific for tetra-acetylated H4 (acetyllysine at positions 5, 8, 12, and 16)

• Additional antibodies can recognize specific single acetylation sites

• These specialized antibodies allow researchers to determine the proportion of H4 molecules modified at specific sites

When designing experiments:

• Researchers must select antibodies that recognize the precise modification pattern of interest

• Validation through inhibition assays using synthetic peptides is essential to confirm specificity

• Controls should include samples with known modification states

• Interpretation must consider that multiple modification patterns may exist simultaneously in biological samples

What evidence exists for ordered histone H4 acetylation and its biological significance?

Research using specific antibodies has revealed important insights about histone H4 acetylation patterns:

• Acetylation of histone H4 does not follow a completely random pattern nor a single fixed order

• In mono-acetylated H4 from human HL-60 cells, only 7% of molecules are acetylated at Lys-5, which is significantly lower than the 25% expected with random acetylation

• For di-acetylated forms, approximately 29% are acetylated at Lys-5 (versus 50% expected randomly)

• For tri-acetylated forms, about 61% are acetylated at Lys-5 (versus 75% expected randomly)

• These patterns indicate Lys-5 and Lys-12 are generally under-used in mono-acetylated H4

• Lys-8 and/or Lys-16 appear to be the first sites acetylated in most cells

Interestingly, a cell-cycle specific pattern exists:

• Mono-acetylated H4 from metaphase HeLa cells shows significantly more acetylation at Lys-5 and Lys-12 than interphase cells

• This metaphase-specific shift suggests H4 acetylation plays a role in chromatin structure modulation during cell division

These findings demonstrate the complex regulation of histone modifications and their potential roles in controlling chromatin accessibility and gene expression.

How can researchers optimize HOS4 antibody performance in immunohistochemistry?

For optimal immunohistochemistry results with HOXC4 antibody:

• Sample preparation:

  • For paraffin-embedded tissues (IHC-P), use recommended dilution of 1:200-400

  • For frozen sections (IHC-F), use a dilution range of 1:100-500

  • Ensure proper fixation to preserve epitope structure while allowing antibody access

• Antigen retrieval optimization:

  • Test multiple retrieval methods (heat-induced with citrate buffer, EDTA, or enzymatic retrieval)

  • Optimize retrieval duration to balance epitope exposure and tissue preservation

• Blocking protocol:

  • Use appropriate blocking solution containing 1-5% BSA or serum

  • Include 0.1-0.3% Triton X-100 for nuclear antigens like HOXC4

  • Sufficient blocking time (1-2 hours) reduces background staining

• Detection system selection:

  • For HRP-conjugated antibodies like the HOXC4 polyclonal antibody, ensure endogenous peroxidase blocking

  • Optimize substrate development time for optimal signal-to-noise ratio

  • Consider amplification systems for low-abundance targets

• Controls:

  • Include positive controls (tissues with known HOXC4 expression)

  • Use negative controls (omitting primary antibody and using isotype controls)

  • Consider using tissues from knockout models when available

What are the mechanisms by which bi-specific antibodies target cancer cells, and how does this relate to HOS4 research?

While not directly related to HOS4, research on bi-specific antibodies provides valuable insights for immunotherapy applications that could be relevant to HOX protein targeting:

Bi-specific antibodies feature two distinct binding domains:

• One arm targets a tumor-specific antigen (e.g., BCMA in myeloma cells)

• The second arm recruits effector cells (typically T cells via CD3)

This mechanism creates an immunological synapse where:

• T cells are brought into close proximity with cancer cells

• The interaction activates T cells without requiring MHC recognition

• Activated T cells release cytotoxic granules and cytokines

• This leads to targeted elimination of cancer cells

Key advantages demonstrated in myeloma research include:

• Effectiveness regardless of genetic features of cancer cells

• Activity in both newly diagnosed and relapsed settings

• Efficacy even in heavily pretreated patients

• Avoidance of T cell exhaustion through direct activation

For HOX research, this approach could be relevant as:

• HOX proteins like HOXC4 have altered expression in various cancers

• A bi-specific approach could potentially target cells with aberrant HOX expression

• The "off-the-shelf" nature of this approach avoids the personalization requirements of other immunotherapies

How do antibody binding kinetics affect experimental outcomes in HOS4-related research?

Antibody binding kinetics significantly impact experimental results:

• Affinity considerations:

  • Higher-affinity antibodies typically provide better sensitivity

  • For nuclear proteins like HOXC4, antibodies must maintain binding during washing steps

  • The KLH-conjugated synthetic peptide approach used to generate HOXC4 antibodies aims to produce high-affinity antibodies

• On/off rate implications:

  • Fast on-rates improve staining efficiency in time-limited protocols

  • Slow off-rates reduce background by maintaining specific binding during washing

  • For techniques like ChIP, antibodies with slow off-rates are particularly valuable

• Concentration and incubation time relationship:

  • HOXC4 antibody application recommendations vary by technique:

    • Western blot: 1:300-5000 dilution

    • ELISA: 1:500-1000 dilution

    • IHC-P: 1:200-400 dilution

    • IHC-F: 1:100-500 dilution

  • These ranges reflect the need to optimize the antibody concentration based on target abundance and detection method

• Temperature effects:

  • Room temperature incubations favor faster kinetics but may increase non-specific binding

  • 4°C overnight incubations often provide better signal-to-noise ratios for nuclear antigens

• Buffer composition effects:

  • The storage buffer for HOXC4 antibody (0.01M TBS pH 7.4 with 1% BSA, 0.03% Proclin300 and 50% Glycerol) is designed to maintain antibody stability and activity

  • Working buffers should be optimized to maintain specific binding while minimizing background

What correlations exist between serum and bronchoalveolar lavage antibodies in respiratory virus research?

While not directly related to HOS4, research on respiratory virus antibodies provides methodological insights relevant to antibody research more broadly:

Recent studies examining antibodies against respiratory syncytial virus (RSV) and influenza A virus found:

• RSV-binding IgA and IgG measurements in serum positively correlated with those in bronchoalveolar lavage (BAL)

• For influenza A virus, serum and BAL IgA antibodies showed positive correlation

• Interestingly, IgG antibodies against influenza A did not show significant correlation between serum and BAL

• Most importantly, virus-specific neutralizing activity did not correlate between serum and BAL samples

These findings demonstrate:

• Antibody levels in circulation don't necessarily reflect levels at sites of infection

• Functional activity (neutralization) may differ from binding antibody levels

• Different pathogens show distinct patterns of antibody compartmentalization

• Measurement of antibodies in both systemic circulation and at target sites provides complementary information

For HOX-related research, these principles highlight the importance of measuring target proteins in the most relevant biological compartment rather than assuming correlation between different sample types.

What validation strategies should researchers employ to confirm HOS4 antibody specificity?

Thorough validation is essential for reliable antibody-based research. For HOXC4 or related antibodies:

• Western blot analysis:

  • Verify single band of expected molecular weight

  • Compare results across different cell types with varying expression levels

  • Include negative controls (non-expressing tissues/cells)

• Peptide competition assays:

  • Pre-incubate antibody with immunizing peptide

  • Should abolish or significantly reduce signal

  • Similar to inhibition assays used for histone H4 antibody validation

• Genetic validation:

  • Test antibody on samples with gene knockout/knockdown

  • Compare expression in tissues known to express/not express the target

  • For HOXC4, compare lymphoid cells (high expression) with other tissues

• Cross-reactivity assessment:

  • Test on related HOX family members

  • Particularly important given the conserved homeobox domain

  • Verify specificity across species if working with non-human models

• Orthogonal detection methods:

  • Compare protein detection with mRNA expression data

  • Use mass spectrometry to confirm identity of detected proteins

  • Employ multiple antibodies targeting different epitopes

• Application-specific validation:

  • For IHC, confirm appropriate subcellular localization (nuclear for HOXC4)

  • For ChIP, verify enrichment at genomic loci with known binding sites

  • For IP-based applications, confirm pull-down of interacting partners

How should researchers optimize storage and handling of HOS4 antibodies to maintain activity?

Proper storage and handling are crucial for maintaining antibody performance:

For HOXC4 polyclonal antibody:

• Store at -20°C

• Aliquot into multiple vials to avoid repeated freeze-thaw cycles

• Maintain in aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300, and 50% Glycerol

General best practices for antibody handling:

• Storage temperature:

  • Long-term: -20°C or -80°C as recommended by manufacturer

  • Working aliquots: 4°C for shorter periods

  • Avoid storing diluted working solutions for extended periods

• Freeze-thaw management:

  • Each freeze-thaw cycle can reduce antibody activity by 5-10%

  • Create small single-use aliquots upon receipt

  • Record number of freeze-thaw cycles for each aliquot

• Buffer considerations:

  • Presence of carriers (BSA, glycerol) provides stability

  • Preservatives (Proclin300) prevent microbial growth

  • Avoid sodium azide when using with HRP-conjugated antibodies

• Concentration effects:

  • More dilute antibodies lose activity faster

  • Maintain stock solutions at recommended concentration (typically 1μg/μl for HOXC4 antibody)

  • Prepare working dilutions fresh when possible

• Environmental factors:

  • Minimize exposure to light (especially for fluorophore-conjugated antibodies)

  • Avoid contamination by using clean pipette tips

  • Centrifuge briefly after thawing to collect solution

What emerging technologies might enhance HOS4 antibody applications in epigenetic research?

Several cutting-edge technologies show promise for advancing research involving HOXC4, HOXB4, and histone H4 antibodies:

• CUT&Tag and CUT&RUN technologies:

  • Improved alternatives to traditional ChIP

  • Higher signal-to-noise ratio for detecting transcription factor binding

  • Require less starting material than conventional ChIP

  • Particularly valuable for HOX proteins that may have relatively low expression levels

• Single-cell epigenomics:

  • Combine antibodies against histone modifications with single-cell sequencing

  • Can reveal cell-to-cell variation in modification patterns

  • Particularly relevant given the findings on cell-cycle specific histone H4 acetylation patterns

• Proximity ligation assays:

  • Detect protein-protein interactions involving HOX transcription factors

  • Can reveal associations between HOX proteins and histone modifying enzymes

  • Provide spatial context for interactions in situ

• CRISPR-based approaches:

  • CUT&Tag combined with CRISPR screens to identify functional targets

  • CUT&Tag with dCas9 fusion proteins for site-specific recruitment

  • Can help elucidate the functional significance of HOX binding events

• Multiplexed imaging technologies:

  • Simultaneous visualization of multiple targets

  • Could reveal co-localization of HOX proteins with specific histone modifications

  • Technologies like Imaging Mass Cytometry, CODEX, or MIBI enable highly multiplexed protein detection

These technologies can address key questions about HOX protein function in development and disease, and about the dynamic relationship between transcription factors and chromatin modifications.

How might HOS4 antibody research contribute to understanding developmental disorders and cancer?

HOX genes, including HOXC4 and HOXB4, play critical roles in development and are frequently dysregulated in cancer:

• Developmental disorders:

  • HOX genes determine positional identity along the anterior-posterior axis during embryogenesis

  • HOXC4 expression increases with differentiation of lymphoid cells, suggesting roles in hematopoiesis

  • HOXC4 is also expressed in differentiated keratinocytes, indicating potential functions in skin development

  • Antibodies enabling precise detection of HOX proteins could help characterize developmental abnormalities

• Cancer research applications:

  • HOX genes are frequently dysregulated in multiple cancer types

  • Altered expression can drive proliferation and survival of cancer cells

  • Specific antibodies can help characterize expression patterns in tumors

  • Understanding the downstream targets of HOX proteins may reveal new therapeutic targets

• Therapeutic development:

  • Research on bi-specific antibodies has shown promise in targeting cancer cells

  • Similar approaches might be developed to target cells with aberrant HOX expression

  • The effectiveness of bi-specific antibodies in heavily pretreated myeloma patients suggests potential for targeting therapy-resistant cancers

• Epigenetic connections:

  • HOX gene expression is regulated by histone modifications

  • The ordered histone H4 acetylation patterns revealed by specific antibodies may influence HOX expression

  • Understanding these connections could reveal how developmental programs are disrupted in disease

• Biomarker potential:

  • Precise quantification of HOX proteins using specific antibodies could identify prognostic or predictive biomarkers

  • Cell-type specific expression patterns might help classify tumors or developmental abnormalities